CytomX Therapeutics (NASDAQ:CTMX) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.17) by 141.18 percent. The company reported quarterly sales of $33.432 million which beat the analyst consensus estimate of $17.514 million by 90.88 percent. This is a 26.71 percent increase over sales of $26.384 million the same period last year.